Enzyvant works to develop breakthrough biotechnologies and transformative therapies for people with devastating rare diseases. The Enzyvant pipeline includes investigational regenerative medicine therapies for T cell–implicated conditions and enzyme therapies for acid ceramidase deficiency. Enzyvant’s investigational therapies have been granted numerous regulatory designations in the US and Europe, including Breakthrough Therapy (BTD), Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric Disease, and Orphan Drug designations. People with rare diseases are fighting for their lives. Enzyvant is dedicated to helping patients win that fight.
On December 27, 2019, Sumitomo Dainippon Pharma Co., Ltd. acquired from Roivant 100% of Sumitovant Biopharma, a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Enzyvant, that comprise Sumitovant.